30 closest matches · ranked by relevance
Open Angle Glaucoma · Ocular Hypertension
Primary: Change From Baseline in Mean Conjunctival Hyperemia Scores at Month 3 — 0.74; 0.86; 0.74; 0.05 Scores on Scale
Pterygium
Primary: Change From Baseline in Overall Conjunctival Hyperemia Score — -0.056; -0.330; -0.352 score on a scale — p=0.218
Hyperemia
Primary: Ocular Redness as Measured by the Investigator Using the Ora Calibra™ Ocular Hyperemia Scale — 1.82; 1.71; 0.58; 1.40 units on a scale
Ocular Redness
Primary: Ocular Redness — 0.46; 0.53; 0.40; 0.49 score on a scale
Rosacea · Erythema
Primary: Responder — 16.7 percentage of responders
Retinal Vein Occlusion · Diabetic Macular Edema · Branch Retinal Vein Occlusion
Primary: Change in Panretinal Leakage Index at Month 12 From Baseline — -3.14 percentage of region of interest in UWFA
Acanthamoeba Keratitis · Fungal Keratitis
Primary: Best Spectacle-Corrected Visual Acuity — 0.614; 0.666 logMAR
Erythema · Rosacea
Primary: Percentage of Participants With at Least a 2-Grade Improvement (Decrease) From Baseline on Both Clinician Erythema Assessment (CEA) and Subject Self-Assessment for…
Assess Phenylephrine on EVP and IOP
Primary: Change in Episcleral Venous Pressure (EVP) — 7.2 mmHg — p=<0.01
Primary Open Angle Glaucoma
Primary: Change in Superior Retinal Capillary Blood Flow (% Zero Pixels) — -0.026; 0.011 % zero pixels — p=0.0016
Prostatic Hypertrophy, Benign
Primary: Baseline-adjusted Least Squared (LS) Means of Peak Urinary Flow (Qmax) at 3 Months After Surgery or Last Observation Carried Forward (LOCF) — 8.3; 9.4; 23.1; 25.7…
Ophthalmic Solutions
Primary: Clinician Assessment of Change From Baseline in Redness at 60 Seconds After First Product Application — 0.31; 0.27; 0.32 units on a scale — p=0.392
Ptosis, Eyelid · Conjunctiva Inflamed · Eye Manifestations
Primary: Change in Palpebral Fissure Height — 1.1; -0.4 mm
Rosacea
Primary: Long Term Safety & Efficacy of CD07805/47 Gel 0.5% in Subjects With Moderate to Severe Facial Erythema Associated With Rosacea. — -1.5; -1.4; -1.5; -1.7 scores on a scale
Rosacea
Primary: Composite Success — 36; 13; 36; 13 participants — p=<0.001
Retinal Vein Occlusion
Primary: Number of Participants Who Had a >30% Decrease in the Aqueous Levels of Various Vasoactive Proteins 4 Weeks After an Injection of Ozurdex — 7; 5; 7; 4 participants
GVHD · Ocular Rosacea · Dry Eye Syndrome
Primary: Number of Participants Who Responded to Intense Pulsed Light (IPL) — 5; 2 participants
Rosacea
Primary: Composite Success — 40; 14; 39; 12 participants — p=<0.001
Erythema · Rosacea
Primary: Percentage of Participants With Treatment-Related Adverse Events — 8.2 percentage of participants
Glaucoma
Primary: 6-month Change in Ophthalmic Artery (OA) Peak Systolic Velocity (PSV) — -.70; 1.84 cm/sec — p=.4414
Rosacea
Primary: Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 5; 0 Participants
Erythematotelangiectatic Rosacea
Primary: Clinical Erythema Assessment (CEA) Score At 6-Month Post-Baseline — 1.6; 2.4 score on a scale
Rosacea · Erythema
Primary: Percentage of Participants Who Are Very Satisfied/Satisfied/Somewhat Satisfied With the Overall Study Treatment — 69.6; 40.4 Percentage of participants — p== 0.0065
Dry Eye
Primary: Sum of the Cooling Scale For Rohto (r) Hydra — 24.6; 12.1 units on a scale
Rosacea
Primary: Proportion of Subjects With Composite Success — 60; 58; 23 Participants
Glaucoma, Open-Angle
Primary: NFC Blood Flow at Baseline and 15 Minutes — 72.52; 83.94; 93.01; 60.50 pL/s
Rosacea
Primary: Composite Success Assessment (CEA) and Patient Self Assessment(PSA). — 32; 48; 33; 46 participants
Rosacea · Chinese Herbal Medicine
Primary: Reduction of Flushing, Erythema, Telangiectasia, Papules, and Pustules — 1; 1.92 score on a scale
Choroidal Neovascularization
Primary: Number of Subjects Avoiding 15 or More Letter Loss of Best Corrected Visual Acuity From Baseline to 12 Months on an Early Treatment Diabetic Retinopathy Study (ETDRS)…
Rosacea
Primary: Percentage of Subjects With Treatment Success at All Time Points 3, 6, 9 and 12 Hours Post-application on Day 29. Treatment Success Was Defined as Having a Clinician…